Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emmanuel Deshayes

Showing results (11-20 of 76) with videos related to

Pageof 8
Sort By:
Clinical Nuclear Medicine|July 1, 2011
Additional Benefit of F-18 FDG PET/CT in the staging and follow-up of pediatric rhabdomyosarcomaFabien Ricard, Sébastien Cimarelli, Emmanuel Deshayes, et al.
International Journal of Molecular Sciences|January 11, 2024
Bisphosphonates as Radiopharmaceuticals: Spotlight on the Development and Clinical Use of DOTAZOL in Diagnostics and Palliative Radionuclide TherapyCéleste Souche, Juliette Fouillet, Léa Rubira, et al.
Current Radiopharmaceuticals|February 29, 2024
"One Method to Label Them All": A Single Fully Automated Protocol for GMP-Compliant <sup>68</sup>Ga Radiolabeling of PSMA-11, Transposable to PSMA-I&T and PSMA-617Juliette Fouillet, Charlotte Donzé, Emmanuel Deshayes, et al.
Cancers|June 28, 2023
Innovation in Radionuclide Therapy for the Treatment of Prostate Cancers: Radiochemical Perspective and Recent Therapeutic PracticesEmmanuel Deshayes, Cyril Fersing, Constance Thibault, et al.
BMC Cancer|December 22, 2022
A prospective, randomized, phase II study to assess the schemas of retreatment with Lutathera® in patients with new progression of an intestinal, well-differentiated neuroendocrine tumor (ReLUTH)Emmanuel Deshayes, Eric Assenat, Laetitia Meignant, et al.
Diagnostics (Basel, Switzerland)|April 23, 2022
Unusual Focal Lung Uptake without CT Abnormality on a Bone Scan: What Might It Mean?Marie-Claude Eberlé, Cyril Fersing, Sophie Guillemard, et al.
Hellenic Journal of Nuclear Medicine|August 5, 2021
Whole body planar and 3D quantitative imaging after <sup>177</sup>Lu-DOTATATE on CZT SPECT/CT device with MEHRS collimator. First reportEmmanuel Deshayes, Cyril Fersing, Kévin Hébert, et al.
European Journal of Drug Metabolism and Pharmacokinetics|May 15, 2023
Clinical Pharmacokinetics of Radiopharmaceuticals from SPECT/CT Image Acquisition by Contouring in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Lu-177 DOTATATE (Lutathera<sup>®</sup>) CaseAnissa Barakat, Lore Santoro, Myrtille Vivien, et al.
EJNMMI Radiopharmacy and Chemistry|January 7, 2021
Implementation and validation of an in-house combined fluorescein/media-fill test to qualify radiopharmacy operatorsCyril Fersing, Emmanuel Deshayes, Sarah Langlet, et al.
Healthcare (Basel, Switzerland)|November 11, 2022
Development and Implementation of a Professional Practices Evaluation during Radiopharmaceuticals AdministrationCharlotte Donzé, Léa Rubira, Lore Santoro, et al.
Pageof 8

Showing results (11-20 of 76) with videos related to

Sort By:
Pageof 8
Clinical Nuclear Medicine|July 1, 2011
Additional Benefit of F-18 FDG PET/CT in the staging and follow-up of pediatric rhabdomyosarcomaFabien Ricard, Sébastien Cimarelli, Emmanuel Deshayes, et al.
International Journal of Molecular Sciences|January 11, 2024
Bisphosphonates as Radiopharmaceuticals: Spotlight on the Development and Clinical Use of DOTAZOL in Diagnostics and Palliative Radionuclide TherapyCéleste Souche, Juliette Fouillet, Léa Rubira, et al.
Current Radiopharmaceuticals|February 29, 2024
"One Method to Label Them All": A Single Fully Automated Protocol for GMP-Compliant <sup>68</sup>Ga Radiolabeling of PSMA-11, Transposable to PSMA-I&T and PSMA-617Juliette Fouillet, Charlotte Donzé, Emmanuel Deshayes, et al.
Cancers|June 28, 2023
Innovation in Radionuclide Therapy for the Treatment of Prostate Cancers: Radiochemical Perspective and Recent Therapeutic PracticesEmmanuel Deshayes, Cyril Fersing, Constance Thibault, et al.
BMC Cancer|December 22, 2022
A prospective, randomized, phase II study to assess the schemas of retreatment with Lutathera® in patients with new progression of an intestinal, well-differentiated neuroendocrine tumor (ReLUTH)Emmanuel Deshayes, Eric Assenat, Laetitia Meignant, et al.
Diagnostics (Basel, Switzerland)|April 23, 2022
Unusual Focal Lung Uptake without CT Abnormality on a Bone Scan: What Might It Mean?Marie-Claude Eberlé, Cyril Fersing, Sophie Guillemard, et al.
Hellenic Journal of Nuclear Medicine|August 5, 2021
Whole body planar and 3D quantitative imaging after <sup>177</sup>Lu-DOTATATE on CZT SPECT/CT device with MEHRS collimator. First reportEmmanuel Deshayes, Cyril Fersing, Kévin Hébert, et al.
European Journal of Drug Metabolism and Pharmacokinetics|May 15, 2023
Clinical Pharmacokinetics of Radiopharmaceuticals from SPECT/CT Image Acquisition by Contouring in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Lu-177 DOTATATE (Lutathera<sup>®</sup>) CaseAnissa Barakat, Lore Santoro, Myrtille Vivien, et al.
EJNMMI Radiopharmacy and Chemistry|January 7, 2021
Implementation and validation of an in-house combined fluorescein/media-fill test to qualify radiopharmacy operatorsCyril Fersing, Emmanuel Deshayes, Sarah Langlet, et al.
Healthcare (Basel, Switzerland)|November 11, 2022
Development and Implementation of a Professional Practices Evaluation during Radiopharmaceuticals AdministrationCharlotte Donzé, Léa Rubira, Lore Santoro, et al.
Pageof 8